Table 1.
Demographic and Clinical Characteristics of 122 AKI Patients Admitted to the Intensive Care Unit
| Patients with AKI n = 122 | Patients with CRRT n = 32 | Patients without CRRT n = 90 | p | |
|---|---|---|---|---|
| Male(%) | 112 (91.8) | 31 (96.9) | 81 (90) | 0.452 |
| Age(years) | 41 (34–50) | 42 (37–55.5) | 41 (31–50) | 0.137 |
| Blood routine and biochemical items | ||||
| Lymphocyte count(× 109) | 0.5 (0.3–0.92) | 0.54 (0.34–1.10) | 0.5 (0.30–0.80) | 0.205 |
| Hemoglobin(g/L) | 98.9 ± 27.4 | 90.7 ± 23.8 | 101.8 ± 28.1 | 0.048 |
| Albumin (g/L) | 28.0 ± 5.8 | 29.3 ± 4.9 | 27.5 ± 6.1 | 0.154 |
| Total Bilirubin (u mol/L) | 8.65 (5.38–13.43) | 7.75 (5.03–15.33) | 9.15 (5.4–13.43) | 0.682 |
| Serum calcium(mmol/L) | 1.92 (1.77–2.09) | 2.00 (1.67–2.19) | 1.92 (1.82–2.05) | 0.375 |
| Items related to HIV infection | ||||
| CD4 counts at ICU admission | 23 (8–78) | 37 (13–122) | 15 (7–69) | 0.043 |
| Patients with HAART | 30 (24.6) | 11 (34.4) | 19 (21.1) | 0.135 |
| Items related to AKI | ||||
| The first Creatinine in Hospital (u mol/L) 72.7 (54–129.3) | 220.1 (70.9–499.1) | 64.5 (51.8–92.6) | <0.001 | |
| The highest Creatinine before in ICU(u mol/L)48.9 (34.7–70.8) | 194.2 (55.4–441.5) | 42.1 (32.8–58.6) | <0.001 | |
| The highest Creatinine during ICU(u mol/L) 159.6 (85.6–331) | 375.4 (293.3–580.0) | 121.6 (79.4–210.5) | <0.001 | |
| Complication | ||||
| Sepsis (%) | 104 (85.2) | 25 (78.1) | 79 (87.8) | 0.245 |
| Septic Shock(%) | 74 (60.7) | 19 (59.4) | 55 (61.1) | 0.863 |
| PCP (%) | 71 (58.2) | 12 (37.5) | 59 (65.6) | 0.006 |
| Respiratory Failure (%) | 81 (66.4) | 15 (46.9) | 65 (72.2) | 0.01 |
| Multiple Organs Support Therapy | ||||
| The use of vasoactive agents (%) | 81 (66.4) | 22 (68.8) | 59 (65.6) | 0.742 |
| Duration of Mechanical ventilation (h) | 131.5 (16–264) | 141.5 (5–225.5) | 124.5 (24–264.0) | 0.788 |
| Severity of illness | ||||
| SOFA score at ICU admission | 8 (4–12) | 12 (6–16) | 7 (4–10) | <0.001 |
| APACHE-II score at ICU admission | 20 (15–28) | 28 (21–34) | 18 (15–23) | <0.001 |
| Outcome | ||||
| Death during in ICU | 61 (50) | 18 (56.3) | 43 (47.8) | 0.41 |
| Length of ICU stay (days), median (IQR) | 9 (5–16) | 8 (5–16) | 9 (5–17) | 0.616 |
| Length of hospital stay (days), median (IQR) | 17 (9–30) | 15 (7–21) | 20 (10–34) | 0.022 |
ICU Intensive care unit, HIV Human immunodeficiency virus, HAART Highly Active Anti-Retroviral Therapy, PCP Pneumocystis carinii pneumonia, CRRT Continuous renal replacement therapy, SOFA, IQR Interquartile range, APACHE-II Acute physiology and chronic health evaluation, version II, SOFA Sequential organ failure assessment, GFR Glomerular Filtration Rate, MPV Mean Platelet Volume
p Value < 0.05 was considered significant and is highlighted in bold